Paper Details

  1. Home
  2. Paper Details

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia.

Author: ArrugaFrancesca, BoccellatoElia, BrunoBenedetto, CosciaMarta, DeaglioSilvia, EfremovDimitar G, GriggioValentina, JonesRebecca, LandesmanYosef, PerutelliFrancesca, RigantiChiara, TodaroMaria, VaisittiTiziana, VitaleCandida

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study evaluated the anti-tumor effects of selinexor, an oral inhibitor of the nuclear export protein XPO1, in combination with chemotherapy drugs or with the PI3Kδ inhibitor idelalisib in chronic lymphocytic leukemia (CLL). Selinexor demonstrated synergistic cytotoxic effects in combination with fludarabine, bendamustine, and idelalisib, and was effective in potentiating the in vivo anti-tumor effects of idelalisib.
Paper Details　
Original Abstract of the Article :
Despite recent relevant therapeutic progresses, chronic lymphocytic leukemia (CLL) remains an incurable disease. Selinexor, an oral inhibitor of the nuclear export protein XPO1, is active as single agent in different hematologic malignancies, including CLL. The purpose of this study was to evaluate ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560255/

データ提供：米国国立医学図書館（NLM）

Targeting Cancer Cells: A New Combination Therapy for CLL

Chronic Lymphocytic Leukemia (CLL) is a complex disease, and despite advancements in treatment, it remains incurable. This study delves into the potential of combining selinexor, a drug that inhibits nuclear export, with other agents like fludarabine, bendamustine, and idelalisib. The researchers found that this combination therapy significantly reduced CLL cell viability and demonstrated synergistic cytotoxic effects, even in the presence of protective stromal cells. These findings provide preclinical evidence that this combination treatment could be an effective strategy for managing CLL.

A synergistic approach to fight cancer

The study demonstrated that combining selinexor with other anticancer drugs significantly reduced CLL cell viability. This synergistic effect could lead to more effective treatments for patients with CLL. The researchers observed that the combined treatment was more effective than each drug alone, highlighting the potential of combining these therapies in the fight against cancer.

New hope for CLL treatment

This study holds exciting promise for the treatment of CLL. The findings suggest that combining selinexor with other existing therapies could be a powerful strategy for fighting this complex disease. This combination approach could lead to better outcomes for patients with CLL, offering them a new hope in the battle against cancer.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the fight against CLL. The synergistic effects of combining selinexor with other agents provide a new pathway for treating this complex disease. This research is like a refreshing oasis in the arid landscape of cancer research, offering new possibilities for patients seeking effective treatment.

Date :
  1. Date Completed 2023-10-09
  2. Date Revised 2023-11-21
Further Info :

Pubmed ID

37805613

DOI: Digital Object Identifier

PMC10560255

Related Literature

Article Analysis
・Effects of idelalisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.